2025 Activity indicators

• 1 competitive European project led: ABSarbo (EULAC)
• 3 competitive national public projects: ISCIII, MICINN
• 2 private projects led
• 2 competitive HR contracts
• 6 publications
• FI: 36.60
• Publications in Q1: 3 (50%)
• Publications in D1: 2 (33%)
• Project evaluators for national institutions: 2 PIs and international institutions (Czech Science Foundation): 1 PI
• Editorial committee member: 1 PI
• 5 active patent families with priority patent:

1. P201430955 "TLR4-specific aptamers and their potential use for stroke treatment." Entry into national phases in 15 countries
2. P201930524 "FPR2 receptor agonist aptamers" with PCT/ES2020/070378 and entry into national phases in the US and Europe
3. EP 18 382 888.8 "Specific aptamers against human MNK1 protein and their use in an MNK1 detection method and as an MNK1 inhibitor" with PCT/EP2019/083547 and entry into national phases in Europe and the US
4. EP24382574.2 "OR2AT4 receptor agonist aptamers and uses thereof"
5. EP24382233.5 "Nucleic acid aptamer for treatment of liver cancer" · An aptamer (ApTOLL), which has passed phases I/IIa for the treatment of stroke, has been licensed to Merck.

• An aptamer (ApTOLL), which has passed phase I/IIa clinical trials for stroke treatment, has been licensed to Merck.
• 5 visiting researchers were hosted for a total of 15.6 months: ATTENBIO; University of Beira Interior (Portugal); University of Naples Federico II (Italy); and University of São Paulo (Brazil).